MedImmune is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland with facilities in Pennsylvania, California, Kentucky, the United Kingdom, and the Netherlands.

With two marketed products and an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health.

MedImmune has a drug development portfolio in oncology and its scientists are actively studying multiple aspects of cancer: tumour cell biology, angiogenesis, tumour immunology and the microenvironment, in order to develop novel therapeutics that will improve patient's lives. http://www.medimmune.com/